uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec(AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008) ~
~ Updated data reflecting all 15 high-dose patients showed substantial treatment effect on both cUHDRS and TFC at 36 months, the timepoint that is the regulatory anchor for the submitted BLA and the confirmatory study; the new analysis demonstrated 80% slowing of disease progression based on cUHDRS (nominal p=0.005) and 67% based on TFC (nominal p=0.011) ~
~ Treatment effect at 48 months likely understated by substantial missing data and survivor bias in updated external control; post hoc analysis using prior external control showed slowing of disease of 54% on cUHDRS (nominal p=0.041) and 68% on TFC (nominal p=0.001) at 48 months ~
~ These positive data are meaningful for Huntington's disease patients who currently have no approved disease-modifying treatment options ~








For anyone who likes browser-based word challenges, Canuckle online game offers a refreshing daily puzzle. It is easy to pick up, and the Canadian-themed answers give it a little personality compared with ordinary word games.
Este contenido puede ser útil para cualquier persona que quiera mantenerse informada sin complicarse demasiado. Consultar Horarios de cada jornada facilita saber cuándo buscar nuevas publicaciones y resultados.